Guidelines for Diagnosis and Treatment of Malaria in India

Overview of Malaria in India

Malaria remains a significant public health challenge in India despite decades of control efforts. India contributes substantially to the global malaria burden and has made commitments toward malaria elimination by 2030. Understanding proper diagnosis and treatment protocols is crucial for healthcare providers across the country.

Types of Malaria in India

India predominantly sees Plasmodium vivax and Plasmodium falciparum malaria cases, with the latter being more severe and potentially fatal. Plasmodium malariae and Plasmodium ovale are less commonly reported in the Indian context.

Diagnosis Guidelines

Early and accurate diagnosis is essential for appropriate treatment and preventing disease transmission. The National Vector Borne Disease Control Programme (NVBDCP) recommends:

• Microscopic examination of peripheral blood smears as the gold standard for malaria diagnosis.
• Rapid Diagnostic Tests (RDTs) in areas where microscopy is not available or feasible.
• Molecular diagnostic techniques for confirmation and research purposes.

All suspected malaria cases should be diagnosed promptly, and results should be communicated to the patient immediately to initiate treatment.

Microscopic Diagnosis

• Thick blood films increase sensitivity for parasite detection.
• Thin blood films help identify the specific Plasmodium species.
• Both require proper staining and trained technicians.

Rapid Diagnostic Tests

• Antigen-based RDTs detect parasite proteins in blood.
• Most commonly available RDTs in India target histidine-rich protein 2 (HRP2) specific to P. falciparum and common Plasmodium lactate dehydrogenase (pLDH) enzyme.
• Healthcare workers can perform RDTs with minimal training.

Treatment Guidelines

The treatment regimen varies based on the infecting species, disease severity, and patient characteristics. NVBDCP recommends the following:

For Uncomplicated P. falciparum Malaria

• Artemisinin-based Combination Therapy (ACT) is recommended.
• Artemether-lumefantrine (AL) is the preferred ACT.
• Alternative ACTs include dihydroartemisinin-piperaquine and artesunate-amodiaquine.
• Completing the full course is essential to prevent treatment failure and drug resistance.

For Severe P. falciparum Malaria

• Parenteral artesunate is the treatment of choice.
• Switch to oral ACT once the patient can tolerate oral medication.
• Proper supportive care is crucial, including monitoring blood glucose, managing complications, and preventing secondary infections.

For P. vivax Malaria

• Chloroquine remains effective in most parts of India, with treatment spanning 3 days.
• To prevent relapses, primaquine (0.25 mg/kg for 14 days) is administered.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency screening is necessary before primaquine administration.

Special Considerations

Pregnancy

• Pregnant women with P. falciparum malaria should receive ACT in the second and third trimesters.
• Quinine is recommended in the first trimester.
• Chloroquine is safe for P. vivax in all trimesters.
• Primaquine is contraindicated during pregnancy.

Children

• Children require weight-based dosing of antimalarial medications.
• Artemether-lumefantrine dispersible tablets are available for pediatric use.
• For severe malaria, parenteral artesunate should be administered as per weight.

Patients With Comorbidities

• Patients with comorbidities need individualized treatment plans.
• Special attention is needed for patients with HIV, diabetes, and chronic diseases.
• Drug interactions should be carefully considered.

Prevention Strategies

Prevention remains essential for malaria control:

Vector Control

• Insecticide-treated mosquito nets
• Indoor residual spraying
• Environmental management to reduce breeding sites

Chemoprevention for High-Risk Groups

• Intermittent preventive treatment in pregnancy
• Seasonal malaria chemoprevention for children in endemic areas

Personal Protection Measures

• Use of repellents
• Wearing protective clothing
• Avoiding outdoor activities during peak mosquito hours

National Malaria Control Programme

India's National Framework for Malaria Elimination (2016-2030) outlines a phased approach to malaria elimination:

1. Pre-elimination phase (2017-2022)
2. Elimination phase (2019-2022)
3. Prevention of re-establishment phase (2023-2030)

The strategy focuses on early diagnosis, complete treatment, efficient vector control, and surveillance. The program emphasizes strengthening health systems, cross-border collaborations, and community engagement to achieve malaria elimination.

Case Examples

Case 1: Uncomplicated P. falciparum Malaria

A 32-year-old male from Rajasthan presented with fever, chills, and headache for five days. Rapid diagnostic testing confirmed P. falciparum infection. He was treated with a 3-day course of Artemether-lumefantrine and recovered completely.

Case 2: P. vivax Malaria in Pregnancy

A 28-year-old pregnant woman in the second trimester from Odisha developed fever with chills. Blood smear examination confirmed P. vivax malaria. She received chloroquine (3 days) followed by weekly chloroquine prophylaxis until delivery. After delivery, she was prescribed a 14-day course of primaquine after G6PD testing to prevent relapse.

Conclusion

Adhering to evidence-based diagnosis and treatment guidelines is crucial for effective malaria management in India. Healthcare providers must stay updated with the latest recommendations to contribute to India's malaria elimination goals. A collaborative approach involving healthcare providers, public health authorities, and communities is essential to reduce the malaria burden and work toward elimination.